Clinical Syndromes-Ocular: Transient Visual Loss

Transient Ischemic Attacks

Volumn , Issue , 2007, Pages 93-115

  Van Stavern, Gregory P ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Central retinal artery occlusion; Ocular ischemic syndrome; Retinal emboli; Transient monocular visual loss; Transient visual loss

Indexed keywords

EID: 34250333958     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470988442.ch4     Document Type: Chapter

References (51)

1. Kaiboriboon K, Piriyawat P, Selhorst JB. Light-induced amaurosis fugax. Am J Ophthalmol 2001; 131: 674-6.
2. Levin LA, Mootha V. Postprandial visual loss. A symptom of critical carotid stenosis. Ophthalmology 1997; 104: 397-401.
3. Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mech-anisms underlying the production of symptoms and the natural history of the disease. Phil Trans R Soc Lond 1999; 354: 1649-73.
4. Miller NR. Embolic causes of transient monocular visual loss. Appearance, source and assessment. Ophthalmol Clin N Am 1996; 9: 359-80.
5. Shults WT. Compressive optic neuropathies. In: Miller NR, Newman NJ, ed. Clinical Neuro-Ophthalmology, 5th edn. Detroit, MI: Williams & Wilkins, 1998: 649-662.
6. Burde RM, Savino PJ, Trobe JD. Clinical Decisions in Neuro-Ophthalmology. Boston: Mosby, 1992.
7. Streifler JY, Eliasziw M, Benavente OR et al. The risk of stroke in patients with first-ever retinal vs hemispheric transient ischemic attacks and high-grade carotid stenosis. North American Symptomatic Carotid Enderaterectomy Trial. Arch Neurol 1995; 52: 246-9.
8. Donders RCJM, for the Dutch TMB Study Group. Clinical features of transient monocular blindness and the likelihood of atherosclerotic lesions of the inter-nal carotid artery. J Neurol Neurosurg Psychiatry 2001; 71: 247-9.
9. Sharma S, Brown GC, Pater JL, Cruess AF. Does a visible retinal embolus increase the likelihood of hemodynamically significant carotid artery stenosis in patients with acute retinal arterial occlusion? Arch Ophthalmol 1998; 116: 1602-6.
10. Mitchell P, Wang JJ, Li W et al. Prevalence of asymptomatic retinal emboli in an Australian urban community. Stroke 1997; 28: 63-6.
11. Merchut MR, Gupta SR, Naheedy MH. The relation of retinal artery occlusion and carotid artery stenosis. Stroke 1988; 19: 1239-42.
12. Ross Russell RW, Page NGR. Critical perfusion of the brain and the retina. Brain 1983; 106: 419-27.
13. Mizener JB, Podhajsky P, Hayreh SS. Ocular ischemic syndrome. Ophthalmology 1997; 104: 859-64.
14. Droy-Lefaix MT, Szabo ME, Doly N. Ischemia and reperfusion-induced injury in rat retina obtained from normotensive and spontaneously hypertensive rats: effect of free radical scavengers. Int J Tiss Reac 1993; 15: 85-91.
15. Golledge J, Wright R, Pugh N, Lane IF. Color-coded Duplex assessment alone before endarterectomy. Br J Surg 1996; 83: 1234-7.
16. Kerty E, Eide N, Horven I. Ocular hemodynamic changes in patients with high-grade carotid occlusive disease and development of chronic ocular ischemia. I. Doppler and dynamic tonometry changes. Acta Ophthalmol Scand 1995; 73: 66-71.
17. Wiznia RA, Pearson WN. Use of transesophageal echocardiography for the detection of a likely source of embolization to the central retinal artery. Am J Ophthalmol 1991; 111: 104-5.
18. Benavente OR, Eliaszaw M, Streifler JY et al. Prognosis after transient mono-cular blindness associated with carotid artery stenosis. N Engl J Med 2001; 345: 1084-90.
19. Benavente OR, Streifler JY, Harbison JW, Eliasszaw M, Hashinski VC, Barnett HJM. Differences between retinal TIA and hemispheric TIA of carotid stenosis origin: observations from NASCET. Neurology 1992; 42 (Suppl. 3): 341.
20. Kline B. The natural history of patients with amaurosis fugax. Ophthalomol Clin N Am 1996; 9: 351-7.
21. Hartmann A, Rundek T, Mast H et al. Mortality and causes of death after first ischemic stroke. The Northern Manhattan Stroke Study. Neurol 2001; 57: 2000-5.
22. Babikian V, Wijman CA, Koleini B et al. Retinal ischemia and embolism. Etiologies and outcomes based on a prospective study. Cerebrovasc Dis 2001; 12: 108-13.
23. Goodwin JA, Gorelick PB, Helgason CM. Symptoms of amaurosis fugax in atherosclerotic carotid artery disease. Neurology 1987; 37: 829-35.
24. Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944; 7: 391-6.
25. Fisher CM. Late-life migraine accompaniments as a cause of unexplained tran-sient ischemic attacks. Can J Neurol Sci 1980; 7: 9-17.
26. Wijman CAC, Wolf PA, Case CS et al. Migrainous visual accompaniments are not rare in late life. The Framingham Study. Stroke 1998; 29: 1539-43.
27. Winterkorn JMS, Kupersmith MJ, Wirtschafter JD, Forman S. Brief report: treatment of vasospastic amaurosis fugax with calcium-channel blockers. N Engl J Med 1993; 32: 396-8.
28. Shahar E, Desatnik H, Brand N et al. Epileptic blindness in children: a localizing sign of various epileptic disorders. Clin Neurol Neurosurg 1996; 98: 237-41.
29. Sadeh M, Goldhammer Y, Kuritky A. Postictal blindness in adults. J Neurol Neurosurg Psychiatry 1984; 46: 566-9.
30. Barry E, Sussman NM, Bosley TM, Harner RN. Ictal blindness and status epilep ticus amauroticus. Epilepsia 1985; 26: 577-84.
31. Hayreh SS. Anterior ischemic optic neuropathy. Arch Neurol 1981; 38: 675-8.
32. Beck RW, Servais GE, Hayreh SS. Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology 1987; 94: 1503-8.
33. Beck RW, Hayreh SS, Podhajsky P et al. Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997; 123: 212-7.
34. Hayreh SS, Podhajsky P, Zimmerman MB. Role of nocturnal arterial hypo-tension in optic nerve head ischemic disorders. Ophthalmologica 1999; 213: 76-96.
35. Hayreh SS, Joos KM, Podhajsky PA et al. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 118: 766-80.
36. Ischemic Optic Neuropathy Decompression Trial Research Group. Character-istics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996; 114: 1366-74.
37. Kawasaki A, Purvin VA, Burgett RA. Hyperhomocysteinemia in young patients with nonarteritic anterior ischemic optic neuropathy. Br J Ophthalmol 1999; 83: 1287-90.
38. Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy is not effective and may be harmful. JAMA 1995; 273: 625-32.
39. Johnson LN, Guy ME, Krohel GB et al. Levodopa may improve vision loss in recent onset, nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2000; 107: 521-6.
40. Fry CL, Carter JE, Kanter MC et al. Anterior ischemic optic neuropathy is not associated with carotid artery atherosclerosis. Stroke 1993; 24: 539-42.
41. Botelho PJ, Johnson LN, Arnold AC. The effect of aspirin on the visual out-come of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1996; 121: 450-1.
42. Kupersmith MJ, Frohman L, Sanderson M et al. Aspirin reduces the incidence of second eye NAION. A retrospective study. J Neuroophthalmol 1997; 17: 1287-90.
43. Rizzo JF, Lessell S. Optic neuritis and ischemic optic neuropathy. Overlapping clinical profiles. Arch Ophthalmol 1991; 109: 1668-72.
44. Hayreh SS, Podhajsky PA, Raman R et al. Giant cell arteritis: validity and reliab-ility of various diagnostic criteria. Am J Ophthalmol 1997; 123: 285-96.
45. Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumato-logy 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 122-8.
46. Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 1998; 125: 521-6.
47. Achkar AA, Lie JT, Hunder GG et al. How does previous corticosteroid treat-ment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994; 120: 987-92.
48. Liu GT, Glaser JS, Schatz NJ et al. Visual morbidity in giant cell arteritis: clinical characteristics and prognosis for vision. Ophthalmology 1994; 101: 1779-85.
49. Cornblath WT, Eggenberger ER. Progressive visual loss from giant cell arteritis despite high dose intravenous methylprednisolone. Ophthalmology 1997; 104: 854-8.
50. Bengtsson BA, Malmvall BE. An alternate day corticosteroid regimen in main-tenance therapy of giant cell arteritis. Acta Med Scand 1981; 209: 347-50.
51. Ferraccioli GF, Di Poi E, Damato R. Steroid sparing therapeutic approaches to polymyalgia rheumatica-giant cell arteritis: state of the art and perspectives. Clin Exp Rheumatol 2000; 18: S58-S60.